NGEN NervGen Pharma Corp.
$1.50▲ +1.35%
Healthcare
Other
Volume 309.2K
Avg Volume (10D) 548.2K
Key Metrics & Fundamentals
Market Cap
$161.28M
P/E Ratio
–
Div Yield
0.00%
52W Range
1.37 - 6.30
% vs 50 MA
-21.22%
% vs 200 MA
-47.99%
RSI-14
35.1
MACD Histogram
+0.0000
Beta (1Y vs SPY)
1.82
Free Cash Flow
-$5.73M
Gross Rev
$0
Gross Profit
$0
EBITDA
$5.02M
COGS
–
Operating Exp
$12.20M
Operating Income
-$12.20M
EBIT
-$12.20M
Pretax Income
-$29.22M
Net Income
-$29.22M
EPS (Diluted)
-0.32
Price & Volume History
Loading chart…
Recent News
NervGen Doses First Patient in Late-Stage Study of Potential Spinal Cord Injury Treatment
MT Newswires · Oct 12, 2026 7:48 AM ET
NervGen Announces First Participant Dosed in RESTORE, a Phase 3 Registrational Study Evaluating NVG-291 in Chronic Spinal Cord Injury
GlobeNewswire · Oct 12, 2026 7:15 AM ET
NervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments
GlobeNewswire · Sep 25, 2026 4:30 PM ET
NervGen to Host Inaugural R&D Day on September 30, 2026
GlobeNewswire · Sep 9, 2026 7:30 AM ET
NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates
GlobeNewswire · Aug 13, 2026 7:30 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See NGEN's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.